Clinical trial · Interventional
Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
Phase II Study of Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
NCT00484601CI-TRIAL-00037026terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual.
Summary
Brief summary (as posted)
This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin. It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Ifosfamide | Drug | Ifosfamide | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ifosfamide and Doxorubicin
- description
- Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma
- interventionNames
- Drug: Ifosfamide
- Drug: Doxorubicin
Primary outcomes (1)
- measure
- To evaluate the overall response rate and toxicity including complete response rate, response duration, time to treatment failure, and survival of ifosfamide and doxorubicin as the second line chemotherapy for patients with advanced NPC
- timeFrame
- May 2008
- description
- Prematured termination, data is not analysed.
Secondary outcomes (1)
- measure
- To correlate EBVDNA titer with clinical response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of NPC * Age \> 18 years old * Measurable metastatic or recurrent disease (s) * Received one prior chemotherapy regimen for metastatic or recurrent NPC which relapsed or became refractory before entry. * ECOG PS 0, 1 or 2 * WBC \> 3,500/uL and ANC \> 1,500/uL Platelet \> 100,000/uL Creatinine - within normal limits SGOT \< 3 X UNL Bilirubin \< 2.0 mg/dL * Ejection fraction \> 45% and no history of myocardial infarction or congestive heart failure in the last 6 months. No history of cardiac ventricular arrythmia or ventricle tachycardia, or uncontrolled atrial fibrillation or supraventricular tachycardia with hemodynamic compromising status. * Random blood glucose level \< 250 mg * Signed informed consent Exclusion Criteria: * Received more than one prior chemotherapy for metastatic or recurrent disease * Ejection fraction \< 45% * WBC \< 3,500/UL or ANC \< 1,500/UL or P/t \< 100,000/UL or SCOT\> 3 x UNL or Bilirubin \> 2.0 mg/dL or Creatinine \> UNL * ECOG PS \> 3 * Hx of myocardial infarction within last 6 months * Random blood glucose level less than or equal 250 mg
References
Publications (0)
Data not yet available
No reference posted for this study.